27 results
F-1
EX-10.26
RDHL
Redhill Biopharma Ltd.
9 Feb 24
Registration statement (foreign)
4:20pm
(no further distribution).
8.5 Transparency Reporting. The Parties understand and agree that Study Drug Sponsor may be subject to various mandatory … transparency reporting requirements, including, but not limited to, 42 U.S.C. § 1320a-7, as codified at 42 CFR §§ 403.900, et seq. (the “Physician
6-K
EX-1.1
RDHL
Redhill Biopharma Ltd.
26 Jan 24
Current report (foreign)
9:31am
to fraud and abuse, payment transparency, and privacy and security of protected health information (collectively, “Health Care Laws”). The Company
6-K
EX-1.1
RDHL
Redhill Biopharma Ltd.
25 Jul 23
Securities Purchase Agreement
12:09pm
, state, local and foreign health care regulatory laws, including without limitation, laws related to fraud and abuse, payment transparency, and privacy
6-K
EX-1.1
fsx 45xc2dj9y8dc
3 Apr 23
Securities Purchase Agreement
8:51am
6-K
EX-1.1
4n8ocid d6
11 May 22
Current report (foreign)
8:56am
424B5
mkgf2 9cgig
22 Nov 21
Prospectus supplement for primary offering
4:30pm
424B5
vdhowdtqrf
18 Nov 21
Prospectus supplement for primary offering
4:17pm
424B5
n6xoffytrh
3 Mar 21
Prospectus supplement for primary offering
4:31pm
424B5
npfh2v 3f1r
1 Mar 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-1
nnam0pbb
27 Jul 20
Current report (foreign)
7:00am
F-3
ijvmae1t ko1mk
24 Jul 19
Shelf registration (foreign)
7:03am
424B5
kspa2nwy 3luz60
23 Jul 19
Prospectus supplement for primary offering
8:31am
424B5
0g5y6f8kti1
10 Dec 18
Prospectus supplement for primary offering
12:03pm
424B5
w6dnhn0b5 xfuhsg
4 Dec 18
Prospectus supplement for primary offering
4:05pm